GET THE APP

Trend of susceptibility profile of Acinetobacter baumannii to ant | 949
Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

Trend of susceptibility profile of Acinetobacter baumannii to antibiotics in Jakarta, Indonesia


2nd International Conference on Translational & Personalized Medicine

August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Enty Tjoa

Scientific Tracks Abstracts: Transl Med

Abstract :

Acinetobacter are widely distributed especially in hospital environment. Acinetobacter poses very little risk to healthy human, on the contrary the microbes cause problems typically in Intensive Care Unit (ICU) and Healthcare setting especially those housing very ill patients. Among all Acinetobacter, A. baumannii accounts about 80% of reported infections. A.baumannii strains are often resistant to many antimicrobial drugs giving difficulty in therapy. We analyzed the susceptibility pattern of all A.baumannii isolated from all kind of specimens that collected from hospitalized patients in ICU in one private hospital in West Jakarta and one public hospital in Central Jakarta, Indonesia, in 2010-2012. Data analysis were using WHONET 5.6 and CLSI breakpoin criteria were applied. A total of 328 A. baumannii isolates from ICU patients of both hospitals showed highly resistance to all antibiotic tested except for Tigecycline and Amikacin. A. baumannii susceptible to Tigecycline were 82% (n=23) in 2010 followed by 50% (n=58) and 34% (n=50) in 2011 and 2012, while for amikacin i.e. 87%, 75%, 50% for the same isolates, came from private hospital. In public hospital the Tigecycline susceptibility pattern were i.e: 80% (n=26), 82% (n=72), 86% (n=99) and for amikacin i.e. 40%, 51%, 25%, in consecutive year, respectively. Those profiles showed Tigecycline and amikacin being less susceptible to A. baumannii isolates by year, but Tigecycline in public hospital showed consistent in susceptibility. A study to identify the resistance genes of A. baumannii in advance was considered to conduct.

Biography :

Enty Tjoa has completed her M.D from Fac.of Med Catholic University of Atmajaya, and Clinical Microbiologist Specialized at the age of 31 years at University of Indonesia. She is interesting in Healthcare Associated Infections, MDRO such as Acinetobacter.

Top

https://sekillinickyazma.com.tr/